BioCell Technology, the branded dietary ingredient supplier, has released the findings of a clinical trial carried out to determine if a correlation existed between the effects of BioCell Collagen in healthy adult females.
These results were presented in a poster session at the American Society for Nutrition (ASN) Nutrition 2019 on June 9, 2019, and are available online.
The poster presentation—entitled The Effects of Skin Aging Associated with the Use of BioCell Collagen in Healthy Adult Females: A Randomized, Double-blind, Placebo-controlled Clinical Trial— will be published as part of the proceedings of Nutrition 2019 by ASN.
The manuscript of the study will be published in the online and print versions of the peer review journal Alternative Therapies in Health and Medicine (ATHM).
Double-blind and placebo-controlled clinical trial
The goal of the study was to determine if a correlation existed between the effects of the dietary supplement, BioCell-Collagen, with changes associated with skin ageing.
The study was a 128-female subject, 12-week, double-blind, placebo-controlled trial. Participants were randomly assigned to an intervention or a placebo.
The intervention consisted of twice daily 500mg oral administration of BioCell Collagen®, a novel hydrolyzed chicken sternal cartilage extract dietary ingredient composed of a naturally-occurring matrix of collagen type-II peptides (≥300 mg), chondroitin sulfate (≥100 mg), and hyaluronic acid (≥50 mg).
For the 113 participants completing the study, BioCell Collagen® supplementation compared to a placebo resulted in:
- Significantly reduced facial lines and wrinkles (P = .019) and crow’s feet lines and wrinkles (P = .05)
- Increased skin elasticity (P = .008) and cutaneous collagen content (P < .001) by 12%
- Improved indicators associated with a more youthful skin appearance based on visual grading and wrinkle width (P = .046)
- Decreased skin dryness and erythema
- No difference existed between the supplement and the placebo for skin surface water content or retention. The supplement was well tolerated, with no reported adverse reactions
“We are very excited to publish the findings of our largest study to date, which further supports the efficacy of our flagship dietary ingredient BioCell Collagen®. Human clinical studies continue to be the gold standard for substantiating dietary supplement claims and we take pride that our licensed partners can take advantage,” said Suhail Ishaq, president of BioCell Technology.
The latest study validates an earlier pilot study that demonstrated similar results—Schwartz SR, Park J. Ingestion of BioCell Collagen, a novel hydrolysed chicken sternal cartilage extract; enhanced blood microcirculation and reduced facial ageing signs. Clin Interven Aging. 2012; 7: 267-273.
Alexander Schauss, PhD, FACN, CFS, Senior Director of Research at AIBMR Life Sciences, and the corresponding author, commented: "An impressive example of how a series of studies, capped by a randomized, double-blind, placebo-controlled, supports a ‘beauty from within’ claim in healthy women.
Schauss continued: "Even more impressive was that the results remained statistically significant even after an intention-to-treat analysis was performed that included the few subjects that dropped out of the study. Such an analysis is seen in only about 15-20% of randomised, placebo-controlled blinded clinical studies published in leading medical journals."
Stephen Schwartz, President and CEO of International Research Services, Inc, added: "It is important that the supplement industry conducts research at the pinnacle of good science and this includes a double-blind, properly populated study like this one."